Cas:4043-69-0 N-[(E)-but-2-enyl]-4-methylaniline manufacturer & supplier

Chemical Name:N-[(E)-but-2-enyl]-4-methylaniline

CAS.NO:4043-69-0

Synonyms:N-[(2E)-but-2-en-1-yl]-4-methylaniline;N-But-2-enyl-p-toluidin;N-(2-butenyl)-p-toluidine;1-p-Toluidino-buten-(2);N-but-2-enyl-p-toluidine

Molecular Formula:C₁₁H₁₅N

Molecular Weight:161.24300

HS Code:2921430090

Physical and Chemical Properties:

Melting point:N/A

Boiling point:257.4ºC at 760 mmHg

Density:0.958g/cm3

Index of Refraction:1.562

PSA:12.03000

Exact Mass:161.12000

LogP:3.05600

Material Safety Information (Applicable for Hazard Chemicals)

RIDADR:

Packing Group:

Contact us for information like N-[(2E)-but-2-en-1-yl]-4-methylaniline chemical properties,Structure,melting point,boiling point,density,molecular formula,molecular weight,N-but-2-enyl-p-toluidine physical properties,toxicity information,customs codes,safety, risk, hazard and MSDS, CAS,cas number,N-(2-butenyl)-p-toluidine Use and application,N-but-2-enyl-p-toluidine technical grade,usp/ep/jp grade.

Related News: An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant. N-[(E)-but-2-enyl]-4-methylaniline manufacturer An FDA inspection also turned up a long list of sanitary problems and bad manufacturing practices at the Emergent plant. N-[(E)-but-2-enyl]-4-methylaniline supplier Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly. N-[(E)-but-2-enyl]-4-methylaniline vendor The FDA issued a stark warning to the public urging them to stop using rapid COVID-19 antigen tests developed by Innova Medical Group, the company previously tapped by the U.K. government for hundreds of millions of kits to help regularly screen the country’s population. N-[(E)-but-2-enyl]-4-methylaniline factory Lilly did show much more conclusively that donanemab, which zeroes in on amyloid plaques, does reduce levels of the aggregates of misfolded proteins in the brain. This is what Biogen also showed with Aduhelm, and it turned out this week to be enough for a full FDA approval, hence the stock bump for Lilly.